The immunological interface: dendritic cells as key regulators in metabolic dysfunction-associated steatotic liver disease.

Autor: Klaimi C; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France., Kong W; Gustave Roussy, INSERM U1015, Villejuif, France., Blériot C; Gustave Roussy, CNRS UMR9018, Metabolic and Systemic Aspects of Oncogenesis for New Therapeutic Approaches, Université Paris-Saclay, Villejuif, France.; Institut Necker Enfants Malades, CNRS, INSERM, Université Paris Cité, France., Haas JT; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Jazyk: angličtina
Zdroj: FEBS letters [FEBS Lett] 2024 Dec 12. Date of Electronic Publication: 2024 Dec 12.
DOI: 10.1002/1873-3468.15072
Abstrakt: Metabolic dysfunction-associated steatotic liver disease (MASLD) refers to a broad spectrum of conditions associating fat accumulation in the liver (steatosis) with varying degrees of inflammation (hepatitis) and fibrosis, which can progress to cirrhosis and potentially cancer (hepatocellular carcinoma). The first stages of these diseases are reversible and the immune system, together with metabolic factors (obesity, insulin resistance, Western diet, etc.), can influence the disease trajectory leading to progression or regression. Dendritic cells are professional antigen-presenting cells that constantly sense environmental stimuli and orchestrate immune responses. Herein, we discuss the existing literature on the heterogeneity of dendritic cell lineages, states, and functions, to provide a comprehensive overview of how liver dendritic cells influence the onset and evolution of MASLD.
(© 2024 The Author(s). FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
Databáze: MEDLINE
Externí odkaz: